The Global Catheter Related Blood Stream Infection Market is estimated to be valued at US$44.67 billion in 2023 and is expected to exhibit a CAGR of 6% over the forecast period 2023 to 2033, as highlighted in a new report published by Coherent Market Insights.
Catheter-related blood stream infection (CRBSI) is a major cause of healthcare-associated infections, resulting in increased morbidity, mortality, and healthcare costs. This market encompasses various products such as antimicrobial catheters, antibiotic lock solutions, and catheter coatings, which are designed to prevent or treat catheter-related infections. These products play a crucial role in reducing the risk of bloodstream infections in patients requiring long-term catheterization, particularly in critical care settings. Furthermore, the rising geriatric population and the increasing prevalence of chronic diseases are driving the demand for catheter-related infection prevention products.
The market growth can be attributed to two major drivers. Firstly, the increasing prevalence of catheter-related infections, especially in the intensive care setting, is propelling the demand for CRBSI prevention products. Secondly, the growing geriatric population, who are more susceptible to infections, is further driving the market growth. The rising number of chronic diseases such as kidney failure, cancer, and diabetes, which require long-term catheterization, is also contributing to the demand for catheter-related infection prevention products. Additionally, technological advancements in catheter design and materials are improving the efficacy of infection prevention products, further boosting market growth.
The global catheter-related bloodstream infection market is expected to witness high growth, exhibiting a CAGR of 6% over the forecast period (2023-2033), due to increasing awareness about infection control and prevention. North America is expected to be the fastest-growing and dominating region in the market, attributed to the presence of advanced healthcare infrastructure, favorable reimbursement policies, and high healthcare expenditure. Key players operating in the market include Citius Pharmaceuticals, CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, AstraZeneca Pharma India Ltd., Glenmark Pharmaceuticals Ltd., Xellia Pharmaceuticals Ltd., and Pfizer. These companies focus on product innovation and strategic collaborations to maintain their market position and cater to the growing demand for CRBSI products and solutions.
Read More
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian